VP, Global Life Sciences

Frost & Sullivan

Nitin has close to 20 years of healthcare industry knowledge, including 10 plus years of consulting expertise focusing on the pharmaceutical and biotechnology sector. His industry expertise covers key healthcare sectors from pharmaceuticals and biotechnology to clinical diagnostics and clinical research. Expertise in Translational R&D (Biologics & Small molecules), Oncology (Brain Tumors; Breast & Prostate Cancer), Antimicrobials (Nanopolymers, Peptides and Quorum Sensing compounds), In-vitro Toxicology.

Nitin has detailed industry and therapeutic area expertise, including knowledge of key emerging and established markets from a market, regulatory and reimbursement point of view. He has an in-depth understanding of healthcare markets across the world from government healthcare structures and policy to end user and market evaluations.

Prior to his current position, Nitin spent 5-10 years each with GE Healthcare (national distributor), Frost & Sullivan Asia & A*STAR Singapore in various roles from strategy, marketing to in-licensing, portfolio management and market planning. He has facilitated several regional and global strategic alliances. At Frost & Sullivan Asia, he established a responsive, multi-million-dollar consulting business unit and he tripled revenues for Japan business in 2 years.

At A*STAR, he championed business transformation initiatives to strengthen Singapore’s position # 1: Pharma Drug Development (D3) # 2: Diagnostics (DxD) Hub # 3: A*START Central #4: Biopharma Manufacturing Hub. Received Excellence Award from Taiwan’s National Biotech agency to design the 5-year blue print for the local industry.

Education: Advanced Management Program (Corporate Strategy & Finance) from Stanford-NUS, MBA (International Business-SPJIMR) and a Bachelor’s degree in Biomedical Engineering (Gold Medalist) from Bombay University.

Latest insights

Wed Jan 30 2019

[Webinar] Life Science Predictions: Decoding 5 Incredible Growth Opportunit...

Fri Mar 13 2020

Did an experimental drug help a U.S. coronavirus patient?

Fri Jan 10 2020

MoneyBall Medicine: Tom Davenport on the Analytics Gap in Healthcare

Wed Dec 18 2019

MoneyBall Medicine – Milind Kamkolkar on Seeing the Forest and the Tr...

Never miss an announcement